Day: February 24, 2021

24. februar 2021Selskabsmeddelelse nr. 319Ændring af vilkår for aktieemissionMed reference til Selskabsmeddelelse nr. 318, hvori bestyrelsen tilbød tegning af aktier i forbindelse med aktieemission på maksimalt DKK 6 millioner ved at udstede 46.154 nye stk. aktier med en nominel værdi på DKK 50 hver til en pris pr. aktie på DKK 130 og med en tegningsperiode fra 22. februar 2021 – fredag den 26. februar 2021, har bestyrelsen besluttet at ændre vilkår for aktieemissionen til følgende vilkår:Kapitalforhøjelse på maksimalt DKK 6 millioner svarende til 51.282 stk. aktier á nominelt DKK 50,00 pr aktieTegningskurs er fastsat til DKK 117 pr. aktie (lukkekursen den 24. februar 2021 med en likviditetsrabat på 7,5%Tegningsperioden er den 24. februar 2021 fra kl. 19:00 og indtil 25. februar 2021 kl. 17:00Aktierne vil blive tildelt efter et ”først...

ORLANDO, Fla., Feb. 24, 2021 (GLOBE NEWSWIRE) — Kalera (Euronext Growth Oslo ticker KAL, Bloomberg: KSLLF), one of the fastest-growing and largest vertical farming companies in the world and a leader in plant science for producing high-quality produce in controlled environments, today announced the appointment of Maria Sastre to its Board of Directors. A seasoned executive with experience in the food, travel, and tourism industries, Sastre brings with her over 25 years of executive leadership and experience and currently sits on the boards of esteemed, Fortune 500, multibillion dollar public and private companies, including General Mills and O’Reilly Auto Parts. The addition of Sastre to the board coincides with Kalera’s rapid expansion into several new markets and its acquisition of Vindara Inc., the first company to develop...

Sýn hf.’s Consolidated Financial Statement for the year 2020 was approved by the board on February 24th, 2021.Main results:Revenue for the fourth quarter (Q4) of 2020 amounted to ISK 5,413 million, an increase by ISK 478 million compared to the same period in 2019. Revenue in the year 2020 increased by ISK 975 million between years, or 4.9%. COVID-19 has had a considerable impact on both roaming- and advertising revenues in the yearEBITDA for Q4 amounted to ISK 1,427 million, compared to ISK 1,409 million Q4 2019. The EBITDA margin was 26.4% in Q4 of 2020 compared to 28.6% in Q4 2019. EBITDA for the year 2020 was ISK 5,739 million, an increase of ISK 230 million from 2019. EBITDA margin was 27.6% for 2020 compared to 27.8% in 2019Loss in Q4 of 2020 amounted to ISK 3 million, compared to a loss of ISK 2,132 million in the same quarter...

Ársreikningur samstæðu Sýnar hf. fyrir árið 2020 var samþykktur á stjórnarfundi þann 24. febrúar 2021.  Helstu niðurstöður: Tekjur á fjórða ársfjórðungi (4F) 2020 námu 5.413 m.kr. sem er aukning um 478 m.kr. frá sama tímabili árið 2019. Tekjur ársins 2020 hækkuðu um 975 m.kr. milli ára, eða um 4,9%. Heimsfaraldur hefur haft talsverð áhrif á bæði reikitekjur og auglýsingatekjur félagsins.EBITDA nam 1.427 m.kr. á 4F í samanburði við 1.409 m.kr. á sama tímabili í fyrra. EBITDA hlutfallið er 26,4% á 4F 2020 samanborið við 28,6% á 4F 2019. EBITDA ársins 2020 nam 5.739 m.kr. og hækkaði um 230 m.kr. miðað við árið 2019. EBITDA hlutfallið er 27,6% á árinu 2020 samanborið við 27,8% á árinu 2019.Tap á 4F 2020 nam 3 m.kr. samanborið við 2.132 m.kr. tap á sama tímabili í fyrra. Tap ársins 2020 nam 405 m.kr. samanborið við 1.748 m.kr. tap árið 2019....

 Press release24 February 2021, 18:15Chairman of the Board at Sdiptech AB (publ) acquires shares via exercise of buy optionsSdiptech’s Chairman of the Board Jan Samuelson has acquired 90,000 shares in Sdiptech AB in connection with the exercise of buy options from Serendipity Group AB.Sdiptech has been informed that Jan Samuelson has called for the exercise of buy options issued by Serendipity Group. The buy options acquired in 2018 give Jan Samuelson the right to buy 90,000 B-shares in Sdiptech from Serendipity Group.As Serendipity Group does not currently own any shares in Sdiptech, the company acquires the corresponding number of shares from its owners, Ashkan Pouya and Saeid Esmaeilzadeh via companies, who thereby reduce their holdings in Sdiptech by 45,000 shares each.Jan Samuelson is also relocating 45,000 shares from his...

Pressmeddelande24 februari 2021, 18:15Styrelseordföranden i Sdiptech AB (publ) förvärvar aktier via lösen av köpoptionerSdiptechs styrelseordförande Jan Samuelson har förvärvat 90 000 aktier i Sdiptech AB med stöd av köpoptioner från Serendipity Group AB.Sdiptech har informerats om att Jan Samuelson påkallat lösen av köpoptioner utställda av Serendipity Group. Köpoptionerna som förvärvades 2018 ger Jan Samuelson rätt att köpa 90 000 B-aktier i Sdiptech från Serendipity Group.Då Serendipity Group för närvarande inte äger några aktier i Sdiptech förvärvar bolaget motsvarande antal aktier från sina ägare, Ashkan Pouya och Saeid Esmaeilzadeh via bolag, som därmed minskar sina innehav i Sdiptech med 45 000 aktier vardera.Jan Samuelson flyttar därtill 45 000 aktier av sitt nuvarande innehav från en depå i sitt eget namn, till sitt bolag Independia...

Financial statement release on 24 February 2021 at 7:15 p.m. (CET)BBS- Bioactive Bone Substitutes Plc’s (“BBS”, “the Company”) Financial Statements Review 1.1.-31.12.2020 (unaudited)Year 2020 in brief (Reference period 2019)Clinical study results were received in February and they were confirmed to fulfil the Company goals. The ARTEBONE® Paste works clinically as well as human autograft.BBS’ patent application”A METHOD FOR PREPARING A BONE PROTEIN PREPARATION AND A BONE PROTEIN PREPARATION” for the product had been accepted in the USA. The Company’s product ARTEBONE® is now patented in all the countries where it has been applied for. The patent application regarding the production is still in progress in the USA.Covid-19 pandemic caused considerable delays in the Company actions.Considerable deficiencies were discovered in the documentation...

BBS-Bioactive Bone Substitutes Oyj: Tilinpäätöstiedote 1.1.2020 – 31.12.2020 (Tilintarkastamaton)Tilinpäätöstiedote 24.2.2021 klo 19.00 (CET)BBS-Bioactive Bone Substitutes Oyj:n (“BBS”, “Yhtiö”) Tilinpäätöstiedote 1.1.2020 – 31.12.2020 (tilintarkastamaton)Vuosi 2020 lyhyesti (vertailukausi 2019)Kliinisen kokeen tulokset saatiin helmikuussa ja niiden voitiin todeta olevan Yhtiön tavoitteiden mukaisia. ARTEBONE® Paste toimii kliinisesti yhtä hyvin kuin ihmisen oma luusiirre.BBS:n patenttihakemuksen ”A METHOD FOR PREPARING A BONE PROTEIN PREPARATION AND A BONE PROTEIN PREPARATION” tuotevaatimukset hyväksyttiin USA:ssa. Nyt yhtiön ARTEBONE®-tuotteelle on myönnetty patentti kaikissa maissa, joissa sitä on haettu. USA:n osalta on vielä menossa tuotteen valmistusta koskeva patenttihakemus.Covid-19 pandemia aiheutti merkittäviä viiveitä...

MINNEAPOLIS, Feb. 24, 2021 (GLOBE NEWSWIRE) — Jamf (NASDAQ: JAMF), the standard in Apple Enterprise Management, is innovating with new patented workflows to streamline daily tasks and overcome challenges faced by customers in the enterprise, healthcare, and education spaces. Our customers are reaching their highest potentials with Apple devices powered by Jamf, and our current patented workflows are just the beginning. Jamf continues to partner with organizations to identify gaps in their existing workflows and find innovative solutions to fill these gaps and ensure a streamlined end-user process.Virtual VisitsWith Virtual Visits powered by Jamf, healthcare organizations can configure and instantly deploy third-party conferencing platforms like Zoom and Microsoft Teams to iPad or iPhone. Providers are able to virtually round to...